SCHEMBL21706356

SCHEMBL21706356

CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B1OC(=O)CN(CCCCCCN)CC(=O)O1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 16/20 0.56
LONP1 P36776 11/20 0.55
PSMB1 P20618 10/20 0.55
PSMB2 P49721 10/20 0.55
PSMB8 P28062 10/20 0.55
PSMB9 P28065 10/20 0.55
PSMB6 P28072 10/20 0.55
PSMB10 P40306 10/20 0.55
PSMB11 A5LHX3 9/20 0.55
PSMA7 O14818 9/20 0.55
PSMA1 P25786 9/20 0.55
PSMA2 P25787 9/20 0.55
PSMA3 P25788 9/20 0.55
PSMA4 P25789 9/20 0.55
PSMA5 P28066 9/20 0.55
PSMB4 P28070 9/20 0.55
PSMB3 P49720 9/20 0.55
PSMA6 P60900 9/20 0.55
PSMA8 Q8TAA3 9/20 0.55
PSMB7 Q99436 9/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21210524 0.90 PSMB5 (0.63) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL21210343 0.90 PSMB5 (0.63) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL21210364 0.89 PSMB5 (0.59) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL23418217 0.89 PSMB5 (0.59) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL18331492 0.88 PSMB5 (0.58) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL15870726 0.88 PSMB5 (0.57) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL30532058 0.88 PSMB5 (0.51) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL30532065 0.88 PSMB5 (0.51) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL30532066 0.88 PSMB5 (0.51) PSMB5LONP1PSMB1PSMB2PSMB8
SCHEMBL30532059 0.88 PSMB5 (0.51) PSMB5LONP1PSMB1PSMB2PSMB8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200323889-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2020-10-15 US disclosed
US-20200046845-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200323889-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY PSMG3, COPB1, PSMA6 PSMB5 18/4885LONP1 1116/4885PSMB1 6/4885
US-20200046845-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CDR2, DDOST, GALC PSMB5 1902/4885LONP1 3967/4885PSMB1 2386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.